Penclomedine in Treating Patients With Solid Tumors or Lymphoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase I trial to study the effectiveness of penclomedine in treating patients with malignant solid tumors or lymphomas. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Penclomedine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed malignancy (solid tumor or lymphoma)

• No history of brain metastases

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Life expectancy: At least 12 weeks

• Performance status: ECOG 0-2

• WBC at least 4,000/mm3

• Absolute neutrophil count at least 1,500/mm3

• Platelet count at least 100,000/mm3

• Bilirubin less than 1.5 mg/dL

• Creatinine normal

• No history of seizure disorder Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas and mitomycin) and recovered

• At least 4 weeks since prior radiotherapy and recovered